Key takeaways
- BPC-157 is a synthetic 15-amino-acid fragment of a protein found in human gastric juice, and nearly all of its literature comes from rodent models published by a single research group in Zagreb.
- Mechanistic work from independent laboratories links BPC-157 to activation of the VEGFR2 receptor on blood-vessel cells and to increased growth-hormone-receptor expression in tendon fibroblasts.
- Consistent findings across models include faster closure of gastric lesions, improved tendon and ligament healing, and interaction with the nitric oxide system, but effect sizes vary and independent replication is limited.
- No randomized human trial of BPC-157 has been published, it is not approved anywhere, and it has been prohibited in sport by WADA since 2022.
BPC-157 is probably the most discussed and least clinically tested peptide in the tissue-repair category. Its literature is large by the standards of an unapproved compound, well over a hundred papers, yet almost all of it describes rats, most of it comes from one academic group, and none of it is a controlled trial in people. That combination explains both the enthusiasm and the skepticism the compound attracts. This note is a map of what the primary studies actually report, organized by model system and mechanism, with attention to which findings have been reproduced outside the originating laboratory.
What BPC-157 is
The name stands for “body protection compound,” a term coined by Predrag Sikiric and colleagues at the University of Zagreb in the early 1990s for a protein they reported isolating from human gastric juice. BPC-157 is a synthetic 15-residue fragment of that protein, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val and a molecular weight of about 1,419 Da. The full parent protein has never been characterized in the way, say, thymosin β4 has, and the “gastric pentadecapeptide” label the Zagreb group prefers reflects where the fragment was found rather than a known physiological role. Two properties recur in the early papers: the peptide is stable in gastric juice for more than a day, unusual for a small peptide, and it showed activity in rodent models of gastric injury when given orally as well as by injection.1
The gastrointestinal work
The Zagreb group’s original interest was cytoprotection, the capacity of the stomach lining to resist damage from alcohol, NSAIDs, stress and other insults. Across dozens of rat studies summarized in the group’s 2011 review, BPC-157 reduced the size of experimentally induced gastric lesions, accelerated healing of anastomoses and fistulas, and counteracted lesions produced by NSAIDs such as indomethacin and by corticosteroids.1 The same review reports protective effects in rodent models of colitis, short-bowel syndrome and esophagitis. The group has stated, in papers from 2006 onward, that BPC-157 entered clinical trials for inflammatory bowel disease under the development codes PL-10 and PLD-116, sponsored by the Croatian pharmaceutical company Pliva.1 No results from those trials have ever been published in a peer-reviewed journal, and the program does not appear to have advanced.
Tendon, ligament and muscle models
The musculoskeletal work is what draws most contemporary interest. Staresinic and colleagues transected the Achilles tendon in rats and reported that BPC-157-treated animals showed better biomechanical strength, larger callus and improved functional scores than controls over the following weeks.2 Krivic and colleagues detached the Achilles from the calcaneus and found improved tendon-to-bone healing, with the additional observation that BPC-157 opposed the impairment of healing produced by a corticosteroid, and Cerovecki and colleagues reported comparable results in a rat medial collateral ligament transection model. A 2019 review by Gwyer and colleagues, outside the Zagreb group, collected these and the other musculoskeletal studies and concluded that the animal data were consistent but that the field lacked independent replication and any human evidence.3
Tendon fibroblasts in culture
The most informative mechanistic work on tendon comes from Chang and colleagues at Chang Gung Memorial Hospital in Taiwan, independent of Zagreb. Working with tendon fibroblasts and explants from rat Achilles, they found that BPC-157 increased the outgrowth of cells from tendon explants, improved fibroblast survival under oxidative stress from hydrogen peroxide, and increased cell migration in an in vitro wound-scratch assay. The migration effect was associated with phosphorylation of focal adhesion kinase (FAK) and paxillin, proteins that link the cytoskeleton to the extracellular matrix, and it was blocked by a FAK inhibitor.4 In a follow-up study, the same group reported that BPC-157 increased expression of the growth hormone receptor in tendon fibroblasts at both the mRNA and protein level, in a dose- and time-dependent manner, and that this made the cells more responsive to growth hormone in proliferation assays.5 The GH-receptor finding is interesting because tendon is a relatively GH-insensitive tissue, and it offers one candidate explanation for the healing observed in whole-animal models.
The best-designed BPC-157 mechanism studies come from laboratories with no stake in the compound’s discovery, and that independence is worth more than any single result.
Angiogenesis and the VEGFR2 finding
A recurring observation in the rodent wound studies was increased new blood-vessel formation at the site of injury. Hsieh and colleagues, also in Taiwan, set out to identify the receptor pathway. Using human umbilical vein endothelial cells, the chick chorioallantoic membrane assay and a rat hind-limb ischemia model, they found that BPC-157 promoted endothelial tube formation and vessel growth, and that this was associated with activation and increased expression of VEGFR2, the principal receptor for vascular endothelial growth factor.6 Downstream, they traced signaling through Akt and endothelial nitric oxide synthase (eNOS). A pharmacological VEGFR2 inhibitor abolished the effect. The peptide did not appear to act by raising VEGF itself; the interpretation was that it sensitized or activated the receptor. This is one of the few papers to propose a specific molecular target for BPC-157, and it has not yet been independently replicated in another laboratory.
The nitric oxide system
From the earliest years, the Zagreb group reported that BPC-157 interacted with nitric oxide (NO) signaling. In a 1997 study, the peptide counteracted both the gastric lesions and the blood-pressure rise produced by L-NAME, an inhibitor of NO synthesis, and also blunted the hypotension produced by L-arginine, the NO precursor.7 That bidirectional pattern, opposing both too little and too much NO, has been reported repeatedly by the group since. The eNOS involvement found by Hsieh’s team provides a plausible molecular link. A separate note, BPC-157 and the Nitric Oxide System, examines this literature in detail.
| Evidence level | Models used | Representative findings | Status |
|---|---|---|---|
| In vitro | Tendon fibroblasts, endothelial cells4,5,6 | Migration via FAK–paxillin; GH-receptor upregulation; VEGFR2 activation | Independent labs; single studies each |
| In vivo, rodent | Gastric lesions, tendon and ligament transection, colitis, ischemia1,3,6 | Faster lesion closure, improved biomechanics, more vessels | Extensive; mostly one group |
| Toxicology and PK | Rats, dogs8,9 | No toxicity at tested doses; rapid clearance | Single sponsor-linked studies |
| Human | — | No randomized trial published; IBD trials announced 2006, unreported1,10 | Absent |
Safety, pharmacokinetics and the human gap
Two papers from a Chinese group associated with a development effort address questions the Zagreb literature largely skipped. Xu and colleagues conducted formal preclinical toxicology in rats and dogs and reported no significant toxicity at the doses tested.8 He and colleagues characterized absorption, distribution, metabolism and excretion, finding rapid clearance and extensive metabolism to small fragments.9 These are useful but are single studies, and toxicology in animals does not substitute for human safety data.
On the human side, the record is nearly empty. A 2025 systematic review of BPC-157 in orthopedic sports medicine identified no randomized controlled trials; the only human reports were a small retrospective case series and a Phase 1 study whose results were not published.10 Reviews from orthopedic and sports-medicine physicians in the past two years reach the same conclusion and add that the peptide is increasingly encountered in clinical practice despite that absence.3,10 Anti-doping laboratories have confirmed BPC-157 in confiscated preparations and developed detection methods, and the World Anti-Doping Agency added it to the prohibited list in 2022 as a non-approved substance. In the United States, FDA placed BPC-157 in Category 2 of its compounding bulks list in 2023, moved it out of that category in April 2026, and in July 2026 an advisory committee narrowly voted to recommend it for the 503A list, a non-binding step that FDA’s own reviewers opposed, and one that concerns pharmacy compounding rather than research supply. The note on the July 2026 advisory votes covers that record in detail.
Reading the evidence
Three features of this literature should shape how any single result is weighed. First, the great majority of studies come from one group, and independent replication of the core in vivo findings is thin. Second, the rodent studies typically report positive results across a very wide range of injury models, which is either evidence of a general mechanism or a signal of publication and design bias; the field has not yet resolved which. Third, no human efficacy or safety data exist. Findings described here are findings in animals and cells, not in people, and research-grade BPC-157 is not a drug.
Where this leaves the researcher
For laboratory work, BPC-157 offers a stable, inexpensive peptide with a credible set of mechanistic leads, VEGFR2 activation, FAK–paxillin signaling in fibroblasts, GH-receptor upregulation and NO-system modulation, each of which is a testable hypothesis rather than an established fact. The most valuable contributions now would be independent replications of the tendon and angiogenesis results with blinded outcome assessment, and dose–response work outside the Zagreb protocols. Because BPC-157 is often studied alongside thymosin β4 fragments, the note BPC-157 vs. TB-500 compares the two, and Peptide Blends in Research discusses the attribution problems that arise when they are combined. Per-lot identity and purity data for Wednesday’s material are in the COA library.
Frequently asked questions
What is BPC-157 and where does it come from?
BPC-157 is a synthetic 15-amino-acid peptide whose sequence was reported as a fragment of a protective protein in human gastric juice by researchers in Zagreb in the early 1990s. The material used in research is made by chemical synthesis, not extracted from tissue. Its parent protein has not been fully characterized.
Has BPC-157 been tested in humans?
Not in any published controlled trial. Clinical trials for inflammatory bowel disease were announced in the mid-2000s but no results were ever published. A 2025 systematic review found no randomized human studies, only a small case series and an unpublished Phase 1 study. All efficacy findings come from animals and cell cultures.
How does BPC-157 work?
The mechanism is not settled. Independent laboratories have linked it to activation of the VEGFR2 receptor on blood-vessel cells, to FAK–paxillin signaling that drives fibroblast migration, and to increased growth-hormone-receptor expression in tendon cells. The originating group has emphasized interaction with the nitric oxide system. Each is supported by a small number of studies.
Is BPC-157 FDA approved or legal?
BPC-157 is not approved as a drug anywhere. In the United States it is sold as a research chemical; its compounding status has shifted, with a non-binding advisory-committee vote in July 2026 recommending it for the 503A list, but no rule has issued and no human efficacy data exist. WADA has prohibited it in sport since 2022. Its legal status for possession varies by country.
Why is most BPC-157 research from one lab?
The peptide was identified and named by Predrag Sikiric’s group at the University of Zagreb, which has published the large majority of studies since the early 1990s. Independent work exists, notably from groups in Taiwan on tendon cells and angiogenesis, but replication of the in vivo findings by unrelated laboratories remains limited.
References & further reading
- Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612–1632. doi:10.2174/138161211796196954 / PMID 21548867
- Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976–983. doi:10.1016/S0736-0266(03)00110-4 / PMID 14554208
- Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153–159. doi:10.1007/s00441-019-03016-8
- Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774–780. doi:10.1152/japplphysiol.00945.2010 / PMID 21030672
- Chang CH, Tsai WC, Hsu YH, Pang JH. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066–19077. doi:10.3390/molecules191119066
- Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323–333. doi:10.1007/s00109-016-1488-y
- Sikiric P, Seiwerth S, Grabarevic Z, et al. The influence of a novel pentadecapeptide, BPC 157, on NG-nitro-L-arginine methylester and L-arginine effects on stomach mucosa integrity and blood pressure. Eur J Pharmacol. 1997;332(1):23–33. doi:10.1016/S0014-2999(97)01033-9
- Xu C, Sun L, Ren F, et al. Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regul Toxicol Pharmacol. 2020;114:104665. doi:10.1016/j.yrtph.2020.104665 / PMID 32334036
- He L, Feng D, Guo H, et al. Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol. 2022;13:1026182. doi:10.3389/fphar.2022.1026182 / PMID 36588717
- Vasireddi N, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025;21(4). doi:10.1177/15563316251355551 / PMID 40756949